GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:01 06/03/2026 pm IST			5-day change	1st Jan Change
2,038.00 ^GBX	-1.83%		-7.41%	+11.70%

05/03	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
05/03	GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report	RE

GSK Chair Jonathan Symonds buys GBP53,000 in shares

Published on 02/06/2026 at 09:49 pm IST

Alliance News

GSK PLC

-1.83%

GSK PLC - London-based pharmaceuticals company - GSK Non-Executive Chair Jonathan Symonds buys 2,500 shares, at a price of GBP21.14, worth GBP52,850, on Thursday in London.

Current stock price: 2,193.00 pence, up 0.6% on Friday afternoon in London

12-month change: up 48%

By Christopher Ward, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about GSK plc

05/03	Illumina, Inc. and Nashville Biosciences, LLC Announce New Proteomics Data Offering and Expansion of Alliance for Genomic Discovery Dataset	CI
05/03	GSK outgoing CEO Emma Walmsley's 2025 total remuneration was 15.7 mln pounds vs 10.6 mln pounds in 2024 - annual report	RE
04/03	When Talk of Talks Moves Markets
04/03	Remember 2022
04/03	Rosebank fundraise; Surface Transforms loses GM deal	AN
04/03	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute	RE
04/03	Fda approves first generic of Flovent HFA for treatment of asthma	RE
04/03	GSK plc completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. for $1.7 billion.	CI
04/03	GSK Completes Purchase of RAPT Therapeutics	MT
03/03	GSK Wraps Up $2.2 Billion Deal to Buy US-based Rapt Therapeutics	MT
02/03	A Very Dangerous Gamble
02/03	GSK : Sell rating from JP Morgan	ZD
02/03	Price targets raised for BP and Shell	AN
02/03	A Leap into the Unknown
27/02	EU regulator backs approval for Moderna's combined COVID and flu vaccine	RE

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

66,841

Sector

Pharmaceuticals

More about the company